OVERSEA CHINESE BANKING Corp Ltd Has $9.48 Million Stake in Pfizer Inc. (NYSE:PFE)

OVERSEA CHINESE BANKING Corp Ltd increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4,103.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 374,145 shares of the biopharmaceutical company's stock after buying an additional 365,245 shares during the period. OVERSEA CHINESE BANKING Corp Ltd's holdings in Pfizer were worth $9,481,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. SBI Securities Co. Ltd. boosted its holdings in Pfizer by 25.3% in the 1st quarter. SBI Securities Co. Ltd. now owns 365,051 shares of the biopharmaceutical company's stock valued at $9,250,000 after purchasing an additional 73,670 shares during the period. Bogart Wealth LLC boosted its holdings in Pfizer by 5.9% in the 1st quarter. Bogart Wealth LLC now owns 387,779 shares of the biopharmaceutical company's stock valued at $9,826,000 after purchasing an additional 21,526 shares during the period. Sigma Planning Corp boosted its holdings in Pfizer by 18.8% in the 1st quarter. Sigma Planning Corp now owns 180,092 shares of the biopharmaceutical company's stock valued at $4,564,000 after purchasing an additional 28,562 shares during the period. Catalyst Financial Partners LLC boosted its holdings in Pfizer by 13.5% in the 1st quarter. Catalyst Financial Partners LLC now owns 19,874 shares of the biopharmaceutical company's stock valued at $504,000 after purchasing an additional 2,358 shares during the period. Finally, Signaturefd LLC boosted its holdings in Pfizer by 11.9% in the 1st quarter. Signaturefd LLC now owns 89,077 shares of the biopharmaceutical company's stock valued at $2,257,000 after purchasing an additional 9,454 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

PFE traded down $0.11 during midday trading on Friday, hitting $24.48. The company had a trading volume of 24,170,431 shares, compared to its average volume of 41,887,979. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a market capitalization of $139.15 billion, a PE ratio of 17.74, a P/E/G ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The firm's 50-day simple moving average is $24.02 and its 200-day simple moving average is $24.75.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.82 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.03%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is 124.64%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PFE. TD Cowen reduced their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Redburn Atlantic reduced their price objective on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Bank of America raised their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Wolfe Research raised their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.